Biomarker-based methods for aiding the diagnosis of stroke

Patent metadata

Field	Value
Publication number	US-10914745-B2
Application number	US-201715457297-A
Country	US
Kind code	B2
Filing date	Mar 13, 2017
Priority date	Dec 2, 2011
Publication date	Feb 9, 2021
Grant date	Feb 9, 2021

Abstract

The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described.

First claim

The invention claimed is:

1. A method for diagnosing stroke in a patient suspected of having a stroke, comprising determining the concentration of at least two biomarkers in an in vitro sample obtained from the patient and establishing the significance of the concentration of the biomarkers by comparing the concentration value for each biomarker with a corresponding control value, wherein the at least two biomarkers are selected from ICAM-1 (intracellular adhesion molecule 1), L-selectin, P-selectin, VCAM-1 (vascular cell adhesion molecule 1), IL-6 (interleukin-6), sTNFR1 (soluble tumour necrosis factor receptor 1), D-dimer and CRP (C-reactive protein), and wherein at least one of the two biomarkers is selected from ICAM-1, L-selectin, P-selectin and VCAM-1, wherein if stoke is diagnosed, a second method is carried out in order to differentially diagnose the stroke type, the second method comprising:
i) determining the concentration of VCAM-1 and one or more biomarkers selected from h-FABP (human fatty acid binding protein), IL-6 and CRP in an in vitro sample obtained from the patient; and
ii) establishing the significance of the concentration of the biomarkers by comparing the concentration value for each biomarker with a corresponding control value, wherein the corresponding control value is the concentration value for the corresponding biomarker determined from an in vitro sample obtained from a transient ischaemic attack patient or patients.

Assignees

• Randox Laboratories Ltd

Inventors

• Lamont John
• Mcconnell Ivan
• Fitzgerald Peter

Classifications

• G01N33/6893 Primary

  related to diseases not provided for elsewhere · CPC title

• G01N33/6863

  Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• G01N2800/2871

  Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event · CPC title

• G01N2800/32

  Cardiovascular disorders · CPC title